GRAIL, Inc., a healthcare company focused on early cancer detection, will announce its second quarter 2026 financial results following the close of market on Wednesday, Aug. 5, 2026. The announcement provides investors with an update on the company's operational and financial performance for the period. Management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and business progress.

Event Details

The live webcast and recorded replay will be available at the investor relations section of GRAIL's website at investors.grail.com. Interested parties are advised to register for the teleconference and join the webcast at least ten minutes before the scheduled start of the call to ensure timely connection. The event is open to all interested parties.

About GRAIL

GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. The company's mission is to detect cancer early when it can be cured. GRAIL focuses on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation. Its targeted methylation-based platform supports screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment, and recurrence monitoring.

GRAIL, Inc. has entered a collaboration with Priority Health to make GRAIL's Galleri multi-cancer early detection (MCED) test available to Priority Health's self-insured employer groups. This partnership aims to enhance cancer screening coverage by integrating the Galleri test into existing plans. Priority Health, a nationally recognized nonprofit health plan serving more than 1.4 million members, is the third largest provider-sponsored health plan in the nation.

Priority Health launched coverage for Galleri in its Thrive and Thrive Plus Medicare Advantage plans in 2025. The latest expansion makes Priority Health the first Michigan health plan to enable its employer groups to easily add the Galleri test to their cancer screening coverage. The collaboration allows employers to integrate the test into customized benefit programs that include Priority Health's extensive provider network and care management services.

Key Details of the Collaboration

The Galleri test is designed to detect multiple types of cancer early, potentially improving treatment outcomes. With a simple blood draw, Galleri screens for many of the deadliest cancers before symptoms appear. When a cancer signal is found, Galleri provides a cancer signal of origin with high accuracy to help guide an efficient diagnostic work-up. The test is supported by rigorous studies in intended use populations and is the only available MCED test with demonstrated performance in patients being screened for cancer.

"Early cancer detection can lower health care costs by enabling less intensive, more effective treatments," said Megan Hall, PhD, vice president of Medical Affairs at GRAIL. "Priority Health is leading the way in innovative employee benefit offerings, and we are excited to collaborate to bring Galleri to their customers while expanding broader market access."

"At Priority Health, we care about helping employers create benefits that truly work for their teams," said Chase Osbourne, senior vice president of employer solutions & innovation at Priority Health. "By partnering with GRAIL, we're making it easier for employers to support early cancer detection and proactive health."